Advancing Patient Care
Together we can generate real-world clinical evidence that matters
Explore Natera sponsored clinical trials in Oncology
BESPOKE Pan Cancer
Goal:
- Study aims to enroll to 5,000 participants across all cancer types and collect robust clinical data longitudinally (5 years)
- Evaluate correlation between ctDNA and outcomes and provider utilization habits of the assay (i.e. setting, cadence)
Contact: bespokepcstudy@natera.com
SCORE
Goal:
- Study aims to enroll participants for initial cancer indications with collections of both blood and tissue in a ctDNA naive setting to evaluate the association between ctDNA testing and outcomes
- To evaluate agreement between Latitude (tissue-free MRD) and Signatera (tissue-informed MRD) results
Contact: scorestudy@natera.com
SIGNAL: SIgnatera Guided INterventionAL Study
Goal:
- An interventional clinical research platform focused on using Signatera™ to guide treatment decisions and determining whether therapy can be escalated, initiated, or adapted based on molecular residual disease (MRD)
Contact: Signalstudy@natera.com